Mirum Pharmaceuticals, Inc. 近日宣布，加拿大卫生部已正式批准其药物Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒。这一授权标志着该药物在加拿大市场的准入，为患有此种罕见肝病的患者提供了新的治疗选择。
Mirum Pharmaceuticals, Inc. 近日宣布，加拿大卫生部已正式批准其药物Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒。这一授权标志着该药物在加拿大市场的准入，为患有此种罕见肝病的患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.